

Supplementary online appendix

Table S1 Univariate and multivariate analyses of predictors for TNFi persistence

Variables	Univariate analysis (n=497)		Multivariate analysis (n=495)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Used in univariate and multivariate analyses				
Age, years	1.000 (0.99 to 1.01)	0.99	0.997 (0.98 to 1.01)	0.66
Sex, female vs male	1.279 (0.93 to 1.76)	0.13	1.256 (0.90 to 1.76)	0.18
Initial therapy, combination therapy vs monotherapy	0.948 (0.70 to 1.29)	0.73	0.956 (0.70 to 1.31)	0.78
BMI, kg/m ²	1.030 (1.01 to 1.05)	0.01	1.011 (0.98 to 1.04)	0.44
CDAI	1.037 (1.02 to 1.05)	<0.001	1.027 (1.01 to 1.04)	0.001
mHAQ	2.307 (1.56 to 3.42)	<0.001	1.585 (1.00 to 2.51)	0.049
PsA duration, years	0.978 (0.96 to 1.00)	0.04	0.982 (0.96 to 1.00)	0.10
Alcohol use, yes vs no	0.913 (0.67 to 1.25)	0.57	1.013 (0.73 to 1.40)	0.94
Smoking: ever vs never			1.015 (0.82 to 1.25)	0.89
Univariate: demographics				
Ethnicity, Hispanic vs non-Hispanic [*]	0.259 (0.11 to 0.63)	0.003		
Race, white vs others	0.566 (0.27 to 1.19)	0.13		
Marital status, married vs others	1.057 (0.73 to 1.53)	0.77		
Education, college or above vs high school or less	1.127 (0.82 to 1.56)	0.47		

Variables	Univariate analysis (n=497)		Multivariate analysis (n=495)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Univariate: disease activity or disability				
Swollen joints, number	1.042 (1.00 to 1.08)	0.03		
Tender joints, number	1.084 (1.06 to 1.11)	<0.001		
Physician global assessment of disease activity, point value	1.016 (1.01 to 1.03)	0.001		
Patient global assessment of disease activity, point value	1.011 (1.00 to 1.02)	0.001		
Physician global assessment of skin, point value [*]	1.006 (1.00 to 1.01)	0.12		
Patient global assessment of skin, point value [*]	1.011 (1.00 to 1.02)	0.001		
Univariate: medical history and risk factors				
History of coronary artery disease, yes vs no [*]	2.111 (1.02 to 4.36)	0.04		
History of MTX, yes vs no	1.702 (1.06 to 2.74)	0.03		
History of hypertension, yes vs no	1.267 (0.90 to 1.79)	0.18		
History of diabetes, yes vs no	0.904 (0.48 to 1.69)	0.75		
Smoking: previous vs never	1.365 (0.96 to 1.93)	0.20		
Smoking: current vs never	1.037 (0.67 to 1.62)			
CRP, mg/L [*]	1.000 (0.98 to 1.01)	0.77		
ESR, mm/h [*]	1.008 (1.00 to 1.02)	0.19		
Etanercept (n=155) vs adalimumab (n=214)	1.051 (0.73 to 1.51)	0.78		
Infliximab (n=110) vs adalimumab (n=214)	0.841 (0.54 to 1.32)	0.45		
Others (n=18) vs adalimumab (n=214)	1.128 (0.39 to 3.22)	0.82		

^{*}Values not recorded for patients enrolled early in the study. Updates to the enrolment form added variables.

BMI, body mass index; CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HR, hazard ratio; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis.

Table S2 Univariate and multivariate analyses of predictors for time to remission

Variables	Univariate analysis (n=380)		Multivariate analysis (n=379)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Used in univariate and multivariate analyses				
Age, years	0.991 (0.98 to 1.00)	0.11	0.999 (0.99 to 1.01)	0.86
Sex, female vs male	0.744 (0.56 to 1.00)	0.046	0.826 (0.61 to 1.11)	0.21
Initial therapy, combination therapy vs monotherapy	1.090 (0.82 to 1.46)	0.56	1.153 (0.85 to 1.56)	0.35
BMI, kg/m ²	0.940 (0.92 to 0.96)	<0.001	0.955 (0.93 to 0.98)	<0.001
CDAI	0.944 (0.91 to 0.98)	0.002	0.964 (0.93 to 1.00)	0.052
mHAQ	0.257 (0.15 to 0.44)	<0.001	0.478 (0.28 to 0.83)	0.008
PsA duration, years	0.999 (0.98 to 1.02)	0.93	0.997 (0.98 to 1.02)	0.77
Alcohol use, yes vs no	1.265 (0.95 to 1.69)	0.11	0.953 (0.70 to 1.29)	0.76
Smoking: ever vs never			0.851 (0.69 to 1.05)	0.14
Univariate: demographics				
Ethnicity, Hispanic vs non-Hispanic [*]	0.777 (0.41 to 1.48)	0.44		
Race, white vs others	0.912 (0.41 to 2.02)	0.82		
Marital status, married vs others	1.014 (0.74 to 1.38)	0.93		
Education, college or above vs high school or less	1.301 (0.97 to 1.75)	0.08		

Variables	Univariate analysis (n=380)		Multivariate analysis (n=379)	
	HR (95% CI)	p-value	HR (95% CI)	p-value
Univariate: disease activity or disability				
Swollen joints, number	0.944 (0.90 to 0.99)	0.01		
Tender joints, number	0.912 (0.85 to 0.98)	0.01		
Physician global assessment of disease activity, point value	0.978 (0.96 to 0.99)	0.001		
Patient global assessment of disease activity, point value	0.976 (0.97 to 0.98)	<0.001		
Physician global assessment of skin, point value [*]	0.981 (0.97 to 0.99)	<0.001		
Patient global assessment of skin, point value [*]	0.991 (0.98 to 1.00)	0.04		
Univariate: medical history and risk factors				
History of coronary artery disease, yes vs no [*]	0.555 (0.25 to 1.26)	0.16		
History of MTX, yes vs no	1.198 (0.79 to 1.81)	0.40		
History of hypertension, yes vs no	0.505 (0.34 to 0.74)	0.001		
History of diabetes, yes vs no	0.496 (0.26 to 0.94)	0.03		
Smoking: previous vs never	0.732 (0.52 to 1.02)	0.07		
Smoking: current vs never	0.654 (0.41 to 1.04)			
CRP, mg/L [*]	1.007 (1.00 to 1.02)	0.16		
ESR, mm/h [*]	0.989 (0.97 to 1.01)	0.25		
Etanercept (n=123) vs adalimumab (n=161)	0.777 (0.55 to 1.11)	0.16		
Infliximab (n=82) vs adalimumab (n=161)	0.902 (0.63 to 1.30)	0.58		
Others (n=14) vs adalimumab (n=161)	1.610 (0.76 to 3.41)	0.21		

^{*}Values not recorded for patients enrolled early in the study. Updates to the enrolment form added variables.

BMI, body mass index; CDAI, Clinical Disease Activity Index; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HR, hazard ratio; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis.